AstraZeneca is reportedly holding discussions with Bristol Myers Squibb regarding a potential merger valued at $400 billion. Various reports, including from the Financial Times, indicate that the talks are focused on a significant tie-up between the two pharmaceutical giants. This move comes after AstraZeneca previously spurned a merger proposal from Pfizer twelve years ago. The potential deal could reshape the landscape of the pharmaceutical industry, with both companies exploring opportunities for collaboration.